OCUL May 2024 10.000 call
| Previous close | 0.1500 |
| Open | 0.1000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 10.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.1000 - 0.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.1k |
GlobeNewswireOcular Therapeutix™ to Present at Two Upcoming Investor Conferences
BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that it will participate at two investor conferences in May: Citizens JMP Life Sciences Confe
- GlobeNewswire
Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024
2024 OIS Retina and ARVO meetings are being held in Seattle, WashingtonBEDFORD, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, announced multiple presentations at th
- GlobeNewswire
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024
First quarter 2024 financial results to be reported on Tuesday, May 7, 2024 Investor Day to replace first quarter 2024 earnings conference call; quarterly calls to resume regular cadence with second quarter 2024 financial results BEDFORD, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies
